OTCMARKET • Last print unknown ago
$1.21—Stale · unknown old
Nuo Therapeutics, Inc. focuses on developing regenerative medicine products, particularly in the field of wound care. Its flagship product, Aurix, is designed to enhance healing through the use of autologous blood-derived products, primarily targeting the U.S. and European markets.
Nuo Therapeutics generates revenue primarily through the sale of its Aurix product, which leverages proprietary technology to process patient blood into a therapeutic product. The company benefits from high gross margins of 66.9% due to the low cost of goods sold associated with its regenerative medicine approach.
Regulatory approvals for new indications of Aurix
Partnerships or collaborations with larger pharmaceutical companies
Clinical trial results impacting product efficacy
Market adoption rates in wound care facilities
Regulatory changes impacting approval processes for medical products
Technological disruption from competing regenerative therapies
Emergence of alternative wound care products with superior efficacy
Potential for larger competitors to enter the regenerative medicine space
High operating losses leading to liquidity concerns
Dependence on future financing to fund R&D
moderate - The demand for medical products can be influenced by economic conditions, but healthcare spending tends to be more stable than other sectors.
Interest rates impact Nuo's cost of capital for R&D investments and can affect valuations, particularly as the company is not yet cash flow positive.
minimal - The company has a negative debt/equity ratio, indicating it is not reliant on debt financing.
growth - Investors seeking high-risk, high-reward opportunities in biotechnology.
high - The stock has shown significant price fluctuations, evidenced by a 1-year return of -32.0%.